-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, and randomized controlled trials (RCT) may not adequately represent patients who are clinically treated with biologics
.
Treatment decisions in PsA can be challenging because of the wide variety of drugs available, although efficacy and safety have been proven in RCTs , and real-world data comparing biologics are limited
.
Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, and randomized controlled trials (RCT) may not adequately represent patients who are clinically treated with biologics
Methods: PsABio is a prospective, observational cohort study of PsA patients receiving first-line to third-line ustekinumab or TNFi treatment at 92 locations in 8 European countries .
Using propensity score (PS) -adjusted multivariate logistic regression, the 6 -month psoriatic arthritis clinical disease activity index (cDAPSA) LDA/ remission and minimal disease activity (MDA)/ very LDA comparison results were evaluated .Methods: PsABio is a prospective, observational cohort study of PsA patients receiving first-line to third-line ustekinumab or TNFi treatment at 92 locations in 8 European countries .
Results: Final analysis of 868 participants ( Utekinumab , n= 426 ; TNFi , n=442 ) with long-term disease and high average cDAPSA scores ( 31.
After using ustekinumab and TNFi to treat patients with psoriatic arthritis for 6 months, both achieved their treatment goals
Source: Source:
Smolen JS, Siebert S, Korotaeva TV , et al .
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Annals of the Rheumatic Diseases2021; 80: 1419-1428.
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Annals of the Rheumatic Diseases 2021; 80: 1419-1428.
Leave a message here
